AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models

被引：2

作者：

Durant, Steve T. ^{[1
]}

Pike, Kurt G. ^{[1
]}

Colclough, Nicola ^{[1
]}

Riches, Lucy ^{[1
]}

Garcia-Trinidad, Antonio ^{[1
]}

Hunt, Thomas ^{[1
]}

Ling, Stephanie ^{[1
]}

Stott, Jonathan ^{[1
]}

Barrett, Ian ^{[1
]}

Zheng, Li ^{[1
]}

Wang, Yingchun ^{[1
]}

Chen, Kan ^{[1
]}

Zhang, Tianwei ^{[1
]}

Reddy, Venkatesh Pilla ^{[1
]}

Sykes, Andrew ^{[1
]}

Johnstrom, Peter ^{[1
]}

Jones, Gemma ^{[1
]}

Pierce, Andrew ^{[1
]}

Karlin, Jeremy ^{[2
]}

Kahn, Jenna ^{[2
]}

Allen, Jasmine ^{[2
]}

Valerie, Kristoffer ^{[2
]}

Illingworth, Ruth ^{[1
]}

Pass, Martin ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] Virginia Commonwealth Univ, Richmond, VA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期

关键词：

D O I：

10.1158/1535-7163.TARG-17-A104

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A104

引用

页数：2

共 12 条

[1] The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
Durant, Stephen T.
Zheng, Li
Wang, Yingchun
Chen, Kan
Zhang, Lingli
Zhang, Tianwei
Yang, Zhenfan
Riches, Lucy
Trinidad, Antonio G.
Fok, Jacqueline H. L.
Hunt, Tom
Pike, Kurt G.
Wilson, Joanne
Smith, Aaron
Colclough, Nicola
Reddy, Venkatesh Pilla
Sykes, Andrew
Janefeldt, Annika
Johnstrom, Peter
Varnas, Katarina
Takano, Akihiro
Ling, Stephanie
Orme, Jonathan
Stott, Jonathan
Roberts, Caroline
Barrett, Ian
Jones, Gemma
Roudier, Martine
Pierce, Andrew
Allen, Jasmine
Kahn, Jenna
Sule, Amrita
Karlin, Jeremy
Cronin, Anna
Chapman, Melissa
Valerie, Kristoffer
Illingworth, Ruth
Pass, Martin
SCIENCE ADVANCES, 2018, 4 (06):
[2] Discovery of the clinical candidate AZD1390: A high-quality, potent and selective inhibitor of ATM kinase with the ability to cross the blood-brain barrier
Pike, Kurt
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
[3] Discovery of the clinical candidate AZD1390: a high-quality, potent, and selective inhibitor of ATM kinase with the ability to cross the blood-brain barrier
Pike, Kurt G.
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[4] Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Karlin, Jeremy
Allen, Jasmine
Ahmad, Syed F.
Hughes, Gareth
Sheridan, Victoria
Odedra, Rajesh
Farrington, Paul
Cadogan, Elaine B.
Riches, Lucy C.
Garcia-Trinidad, Antonio
Thomason, Andrew G.
Patel, Bhavika
Vincent, Jennifer
Lau, Alan
Pike, Kurt G.
Hunt, Thomas A.
Sule, Amrita
Valerie, Nicholas C. K.
Biddlestone-Thorpe, Laura
Kahn, Jenna
Beckta, Jason M.
Mukhopadhyay, Nitai
Barlaam, Bernard
Degorce, Sebastien L.
Kettle, Jason
Colclough, Nicola
Wilson, Joanne
Smith, Aaron
Barrett, Ian P.
Zheng, Li
Zhang, Tianwei
Wang, Yingchun
Chen, Kan
Pass, Martin
Durant, Stephen T.
Valerie, Kristoffer
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (08) : 1637 - 1647
[5] The brain-penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury
Ahmed, Zubair
Tuxworth, Richard I.
CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (07):
[6] Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390
Pike, Kurt G.
Hunt, Thomas A.
Barlaam, Bernard
Benstead, David
Cadogan, Elaine
Chen, Kan
Cook, Calum R.
Colclough, Nicola
Deng, Chao
Durant, Stephen T.
Eatherton, Andrew
Goldberg, Kristin
Johnstro''m, Peter
Liu, Libin
Liu, Zhaoqun
Nissink, J. Willem M.
Pang, Chengling
Pass, Martin
Robb, Graeme R.
Roberts, Caroline
Schou, Magnus
Steward, Oliver
Sykes, Andy
Yan, Yumei
Zhai, Baochang
Zheng, Li
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (04) : 3090 - 3111
[7] Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor
Zhang, Jian
McAndrew, Nicholas P.
Wang, Xiaojia
Du, Yiqun
DiCarlo, Brian
Wang, Mei
Chen, Kan
Yu, Wenlei
Hu, Xichun
BREAST CANCER RESEARCH, 2023, 25 (01)
[8] Discovery of a potent, selective, and orally available SHP2 inhibitor that can penetrate blood-brain barrier
Kim, Miyeon
Kim, Dongsu
Yoon, Kyeong Jin
Jeon, Yeejin
Park, Dohyun
Lee, Mijung
Jeon, Dahye
Jang, Soyeon
Kim, Jinhwan
Kim, Eunji
Park, Jihoon
Hong, Victor
Lim, Sang Kyun
Choi, Sungpil
CANCER RESEARCH, 2023, 83 (07)
[9] Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2
Liu, Xingui
Kalogeropulou, Alexia F.
Domingos, Sofia
Makukhin, Nikolai
Nirujogi, Raja S.
Singh, Francois
Shpiro, Natalia
Saalfrank, Anton
Sammler, Esther
Ganley, Ian G.
Moreira, Rui
Alessi, Dario R.
Ciulli, Alessio
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2022, 144 (37) : 16930 - 16952
[10] A preclinical PK/PD model based on a mouse glioblastoma survival model for AZD1390, a novel, brain-penetrant ATM kinase inhibitor, to predict the inhibition of DNA damage response induced by radiation and the human efficacious dose
Reddy, Venkatesh Pilla
Sykes, Andy
Colclough, Nicola
Durant, Stephen T.
O'Connor, Lenka Oplustil
Hoch, Matthias
Bruna, Nuria Buil
De Vita, Serena
Merchant, Melinda
Pass, Martin
CANCER RESEARCH, 2019, 79 (13)

← 1 2 →